Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

8.1%

49 terminated/withdrawn out of 602 trials

Success Rate

89.0%

+2.4% vs industry average

Late-Stage Pipeline

21%

129 trials in Phase 3/4

Results Transparency

40%

157 of 396 completed trials have results

Key Signals

82 recruiting157 with results36 terminated13 withdrawn

Enrollment Performance

Analytics

N/A

140(35.3%)

Phase 3

114(28.7%)

Phase 1

75(18.9%)

Phase 2

48(12.1%)

Phase 4

15(3.8%)

Early Phase 1

5(1.3%)

397Total

N/A(140)

Phase 3(114)

Phase 1(75)

Phase 2(48)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (602)

Showing 20 of 602 trials

NCT01859299Completed

Intestinal Bacteria and Ocular Inflammatory Disease

Role: lead

NCT00038727Phase 3Completed

Diabetes Prevention Program Outcomes Study

Role: collaborator

NCT02617966Recruiting

Rod and Cone Mediated Function in Retinal Disease

Role: lead

NCT01778543Recruiting

Pathogenesis and Genetics of Microphthalmia, Anophthalmia and Uveal Coloboma (MAC)

Role: lead

NCT00055029Completed

Clinical and Genetic Studies of X-Linked Juvenile Retinoschisis

Role: lead

NCT02055248Completed

Study on Moebius Syndrome and Congenital Facial Weakness Disorders

Role: collaborator

NCT01736293Active Not Recruiting

Natural History of Eye Diseases Related to ABCA4 Mutations

Role: lead

NCT01352975Completed

Study of Dark Adaptation in Age-Related Macular Degeneration

Role: lead

NCT00594672Active Not Recruiting

Age-Related Eye Disease Study (AREDS) Follow-Up

Role: lead

NCT02941263Completed

Natural History of Geographic Atrophy Associated With Age-Related Macular Degeneration

Role: lead

NCT02077894Recruiting

Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions

Role: lead

NCT02471287Recruiting

Genetics of Inherited Eye Disease

Role: lead

NCT02741440Active Not Recruiting

Natural History of Spinocerebellar Ataxia Type 7 (SCA7)

Role: lead

NCT01145196Recruiting

Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene

Role: lead

NCT07490444Phase 2Recruiting

Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome

Role: collaborator

NCT07691463Not ApplicableRecruiting

Evaluating How Well Different Types of Light-sensitive Cells in the Eye Contribute to Its Focusing Ability

Role: collaborator

NCT00481546Phase 1Completed

Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations

Role: collaborator

NCT06790784Phase 3Recruiting

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

Role: collaborator

NCT05145491Not ApplicableRecruiting

Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM

Role: collaborator

NCT05844982Phase 3Recruiting

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

Role: collaborator